Aradigm’s Inhaled CF Drug Passes Phase II Proof Of Concept
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm slates conference call for mid-July to provide details.
You may also be interested in...
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.